menu
    • menu

    Company profile for DemeRx

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    DemeRx is a clinical stage pharmaceutical development company advancing two lead drug candidates for medically assisted therapies for opioid addiction, Ibogaine and its active metabolite - Noribogaine. Ibogaine is an indole alkaloid from equatorial Africa. DemeRx is advancing Ibogaine for medication-assisted detoxification in controlled medically supervised inpatient settings. Noribogaine is being developed for office-based op...
    DemeRx is a clinical stage pharmaceutical development company advancing two lead drug candidates for medically assisted therapies for opioid addiction, Ibogaine and its active metabolite - Noribogaine. Ibogaine is an indole alkaloid from equatorial Africa. DemeRx is advancing Ibogaine for medication-assisted detoxification in controlled medically supervised inpatient settings. Noribogaine is being developed for office-based opioid dependent withdrawal treatment and for detoxification of incarcerated addicts.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DemeRxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Life Science and Technology Park, 1951 NW 7th Ave, Suite 300, Miami Fl 33136
    Telephone
    Telephone
    (786) 347-3500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://demerx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DemeRx Secures $1.7M Nih Grant For Neuroplastogen DMX-1001 In AUD
    DemeRx Secures $1.7M Nih Grant For Neuroplastogen DMX-1001 In AUD

    07 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251007260262/en/DemeRx-Awarded-%241.7-Million-National-Institutes-of-Health-Grant-to-Advance-Potential-First-in-Class-Neuroplastogen-Drug-Candidate-DMX-1001-for-Alcohol-Use-Disorder-AUD

    BUSINESSWIRE
    07 Oct 2025
    Share Share
    DemeRx and Atai get MHRA nod to start trial of ibogaine for opioid use disorder
    DemeRx and Atai get MHRA nod to start trial of ibogaine for opioid use disorder

    10 Mar 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/ibogaine-demerx-atai-mhra-clinical-trial/

    CLINICALTRIALSARENA
    10 Mar 2021
    Share Share
    MHRA green light for DemeRx’s opioid use disorder trial
    MHRA green light for DemeRx’s opioid use disorder trial

    10 Mar 2021

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/mhra_green_light_for_demerxs_opioid_use_disorder_trial_1364958

    Lucy Parsons PHARMATIMES
    10 Mar 2021
    Share Share
    DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a
    DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a

    10 Mar 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/demerx-receives-mhra-approval-for-dmx-1002-ibogaine-to-commence-phase-12a-study-as-first-clinical-trial-in-opioid-use-disorder-in-the-uk-301244144.html

    PRNEWSWIRE
    10 Mar 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search